Long term androgen deprivation therapy in prostate cancer

BMJ

Volumn 337, Issue 7673, 2008, Pages 771-772

  Ockrim, Jeremy L ^a   Abel, Paul D ^b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; GONADORELIN;

ANDROGEN THERAPY; EDITORIAL; HUMAN; INSULIN SENSITIVITY; LONG TERM CARE; MEDICAL RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; UNITED STATES; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG POTENTIATION; MALE; PROSTATE TUMOR; RISK FACTOR;

ANDROGEN ANTAGONISTS; CARDIOVASCULAR DISEASES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 53649084333     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.a1361     Document Type: Editorial

References (11)

1. Byar DP. Proceedings: the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973;32:1126-30.
2. Walsh PC, DeWeese TL, Eisenberger MA. A structured debate: immediate versus deferred androgen suppression in prostate cancer - evidence for deferred treatment. J Urol 2001;166: 508-15.
3. Ockrim J, Lalani el-N, Abel P. Therapy insight: parenteral estrogen treatment for prostate cancer - a new dawn for an old therapy. Nat Clin Pract Oncol 2006;3:552-63.
4. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008 Mar 18 [Epub ahead of print].
5. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289-95.
6. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS, and the Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493-500.
7. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
8. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study. Ann Intern Med 2001;135:1-8.
9. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56.
10. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99:1516-24.
11. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005;103:1615-24.